Oncogene Overlap Analysis of Circulating Cell-free Tumor DNA to Explore the Appropriate Criteria for Defining MET Copy Number-Driven Lung Cancer.

ABSTRACT:

Introduction

Defining clinically relevant MET amplification levels in non-small cell lung cancer (NSCLC) remains challenging. We hypothesize that oncogene overlap and MET amplicon size decline with increase in MET plasma copy number (pCN), thus enriching for MET-dependent states.

Patients and methods

We interrogated cell-free DNA NGS results of 16,782 patients with newly diagnosed advanced NSCLC to identify those with MET amplification as reported using Guardant360. Co-occurring genomic mutations and copy number alterations within each sample were evaluated. An exploratory method of adjusting for tumor fraction was also performed and amplicon size for MET was analyzed when available.

Results

MET amplification was detected in 207 (1.2%) of samples. pCN ranged from 2.1

SUBMITTER: Tsui DCC 

PROVIDER: S-EPMC10552597 | biostudies-literature | 2022 Nov

REPOSITORIES: biostudies-literature